However, the studies conducted so far did not detect a reliable early biomarker, although the existing data overall suggest that I-FABP is a promising biomarker for NEC with the potential to improve its diagnostic value when combined with other markers of intestinal damage such as TFF3. This evidence concerns the gene TFF3 and necrotizing enterocolitis.